Predict response to pre-operative erlotinib in a blinded test set (n=13) of NSCLC patients with phosphorylationbased peptide-biomarkers obtained in a training set (n=15). Subcategories of NSCLC patients may benefit from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI's). Patients with cancers that harbor mutated EGFR have a higher chance of response, whereas those with kRAS mutations are unlikely to respond. However patients lacking EGFR mutations may respond as well (1). At present, there are no tests to identify likely responders more reliably than by mutation testing. Previously (2), we have shown that a prediction model based on kinase activity profiles in the presence and absence of a kinase inhibitor predicted erlotinib response of NSCLC patients in a neoadjuvant setting. The aim of the current study was to evaluate this classifier on patient tumor samples (test set), of which the response was disclosed only after classification as responder or non-responder.
Background

Methods
For this study, fresh frozen tumor tissue was used from NSCLC patients (stage IA-IIIA) included in the M06NEL study (1). Preoperative treatment comprised one tablet of 150 mg erlotinib daily for a period of 3 weeks. Surgical resection involved a radical resection of the tumor and regional lymph nodes. Response evaluation to neo-adjuvant treatment was based on metabolic changes and histological assessment of the surgical specimens according to Junker et al (3), e.g. residual vital tumor, signs of therapy related regression. Patients showing stable disease and progressive disease were grouped as non-responders. All specimens were analyzed for EGFR and kRAS mutation status. Fresh frozen tissue cryosections were lysed in M-Per buffer supplemented with phosphatase and protease inhibitors. Kinase activity profiles in the presence and absence of spiked in erlotinib were determined on PamChip® peptide microarrays essentially as described in (4) 
